1. Home
  2. RZLT vs BNTC Comparison

RZLT vs BNTC Comparison

Compare RZLT & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rezolute Inc. (NV)

RZLT

Rezolute Inc. (NV)

SELL

Current Price

$4.00

Market Cap

352.1M

Sector

Health Care

ML Signal

SELL

Logo Benitec Biopharma Inc.

BNTC

Benitec Biopharma Inc.

SELL

Current Price

$8.08

Market Cap

315.4M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
RZLT
BNTC
Founded
2010
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
352.1M
315.4M
IPO Year
2011
2020

Fundamental Metrics

Financial Performance
Metric
RZLT
BNTC
Price
$4.00
$8.08
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
8
Target Price
$10.40
★ $23.75
AVG Volume (30 Days)
★ 1.5M
173.2K
Earning Date
11-05-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 23.47
6.67
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2,517.77
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.07
$7.89
52 Week High
$11.17
$14.39

Technical Indicators

Market Signals
Indicator
RZLT
BNTC
Relative Strength Index (RSI) 46.33 38.65
Support Level $3.58 N/A
Resistance Level $4.22 $13.87
Average True Range (ATR) 0.36 0.68
MACD -0.01 -0.01
Stochastic Oscillator 35.74 0.00

Price Performance

Historical Comparison
RZLT
BNTC

About RZLT Rezolute Inc. (NV)

Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. The company has a single reportable segment, which includes all of its activities as a clinical-stage biopharmaceutical company.

About BNTC Benitec Biopharma Inc.

Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.

Share on Social Networks: